MediWound's NexoBrid Triumphs in Burn Care Study
Express News | Mediwound Announces Positive Results From the U.S. Nexobrid® Expanded Access Protocol (Next)
MediWound Announces Positive Results From the U.S. NexoBrid Expanded Access Protocol (NEXT)
MediWound to Report Second Quarter 2024 Financial Results
Can MediWound (MDWD) Climb 57.49% to Reach the Level Wall Street Analysts Expect?
MediWound Reinforces Wound Therapy EscharEx Data Ahead of Phase III Trial
Oppenheimer Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $36
Mediwound (MDWD) Receives a Buy From Oppenheimer
MediWound Announces Publication of the EscharEx Phase II ChronEx Study Results for Venous Leg Ulcers
MediWound Ltd. (NASDAQ:MDWD) Stocks Shoot Up 43% But Its P/S Still Looks Reasonable
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating
MediWound Price Target Maintained With a $28.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $28 Price Target
MediWound Analyst Ratings
MediWound Accelerates DFU Treatment With EIC Funds
Express News | MediWound Selected For €16.25M Funding From The European Innovation Council Accelerator Program
Express News | Mediwound Announces €16.25 Million Funding From the European Innovation Council Accelerator Program
Express News | Mediwound Ltd : Maxim Group Raises Target Price to $30 From $25
Press Release: MediWound Announces EUR16.25 Million Funding From the European Innovation Council Accelerator Program
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $28